Ispire Posts 33% Q4 Revenue Growth as Shares Drop 9.7%

Ispire Technology Inc (ISPR) told investors on its fiscal fourth-quarter 2026 earnings call that revenue grew 33% year over year with a narrower adjusted EBITDA loss, and that newly granted Malaysian vapor and nicotine pouch licenses position it for fiscal 2027; the shares last traded at 1.30, down 9.72% on the day.

Ispire Technology Inc (ISPR) used its fiscal fourth-quarter 2026 earnings call to make a simple argument: the top line is growing again, the cash burn is shrinking, and the next phase of the business will be built in Malaysia rather than in the United States. The company reported 33% revenue growth for the quarter and a narrower adjusted EBITDA loss, and framed newly granted Malaysian vapor and nicotine pouch licenses as the platform for what it described as a transformational fiscal 2027.

Shareholders were not immediately persuaded. The stock last traded at 1.30, down 9.72% from the prior close of 1.44, having swung between 1.21 and 1.49 during the session, according to market data as of 20:00 GMT on Wednesday, 16 September 2026. That drop came on a day when the broad tape was only modestly lower: SPDR S&P 500 ETF Trust closed at $754.05, off 0.44%, and the Invesco QQQ Trust tracking the Nasdaq 100 finished at $704.72, essentially flat at +0.03%. The Dow-tracking SPDR Dow Jones Industrial Average ETF fell 1.15% to $515.22. In other words, this was a company-specific reaction, not a market one.

Why a 33% growth quarter can still disappoint

For a micro-cap vapor hardware and licensing business, a one-third increase in quarterly revenue is a real result. But growth percentages carry less weight when the starting base is small and when the market is trying to work out how much more cash the company needs before it turns profitable. Adjusted EBITDA — earnings before interest, taxes, depreciation and amortisation, with certain one-off and non-cash items stripped out — narrowed, which is the direction that matters. It is still a loss.

That combination, improving but unfinished, tends to put the burden of proof on the next few quarters rather than the one just reported. A stock that moves nearly 10% lower on a growth-and-narrowing-loss print is usually telling you that investors had already priced the improvement, or that something in the outlook, the margin mix or the balance-sheet commentary was read as a caution. The day's low of 1.21 against a high of 1.49 shows a shareholder base that is small, thinly traded and quick to reprice.

What the Malaysian licenses actually change

The strategic centrepiece of the call was regulatory rather than operational. Ispire said it has secured Malaysian licenses covering both vapor products and nicotine pouches. Two things follow from that.

• A regulated route to market in a jurisdiction that is formalising the category. A license is a barrier to entry. Where a government moves from an unregulated grey market to a permitted, licensed one, incumbents with paperwork in hand gain pricing power and distribution access that unlicensed sellers lose.
• Exposure to nicotine pouches, not just devices. Pouches are an oral, tobacco-free format with a different manufacturing profile and different economics from hardware. Adding them alongside vapor broadens the product set Ispire can sell through the same regulated channel.

The company's own framing, reported from the earnings call by GuruFocus, is that these licenses set the stage for fiscal 2027. That is a forward claim, and it is the one investors will be testing.

The United States problem this is meant to solve

Vapor companies selling into the United States have spent years navigating an authorisation regime that has cleared very few products, alongside state-level flavour restrictions, enforcement actions against unauthorised imports and retailer liability. The practical consequence for a small manufacturer is unpredictable demand and a compliance bill that does not scale down.

Geographic diversification into a market where the company holds explicit licenses is a rational answer to that. It is not a complete one. Shifting the growth story offshore raises new questions that the reported figures do not yet answer: how large the Malaysian addressable market is, what gross margin the licensed products carry, how quickly distribution can be stood up, and whether the revenue arrives inside fiscal 2027 or later. A license is permission to compete, not a purchase order.

The three tests for fiscal 2027

Judging whether this quarter was an inflection or a waypoint comes down to a short list.

• Does the EBITDA loss keep narrowing, quarter after quarter? A single improvement is noise. Three consecutive ones is a trend, and it is what a company needs to show before the market will underwrite a path to breakeven.
• Does revenue growth hold its rate as the base gets bigger? Sustaining a growth rate like 33% becomes harder with every quarter of success. Investors will want to see the Malaysian contribution named separately so that new-market traction can be distinguished from the legacy business.
• How is the growth funded? At a share price of 1.30, equity is an expensive currency. Any capital raised to build out Malaysian supply and distribution dilutes existing holders, which is one reason micro-caps with unfinished profitability trade with this much volatility.

How to read the stock from here

The gap between the operating narrative and the share-price reaction is the story of this print. Management is describing a company that has fixed its growth engine and found a regulated market to grow into. The market, on the day, marked the shares down nearly a tenth. Both can be true at once: the direction of travel improved, and the evidence is not yet sufficient to change how the equity is valued.

For anyone following the name, the reporting calendar now matters more than the headline percentage. Fiscal 2027 quarters will show whether Malaysian licenses convert into shipped product and collected cash, and whether the loss line keeps closing. Until then, ISPR remains a small, volatile security where a single session can move the price further than a full quarter of reported improvement.

Key facts

• ISPR last price: 1.30, down 9.72% from a prior close of 1.44 (as of 20:00 GMT, 16 Sep 2026)
• Q4 FY2026 revenue growth: 33% year over year
• Profitability: Adjusted EBITDA loss narrowed; still a loss
• Strategic driver: New Malaysian vapor and nicotine pouch licenses, aimed at fiscal 2027

Frequently asked questions

What did Ispire Technology report for its fiscal fourth quarter of 2026?

Ispire Technology reported 33% revenue growth for the fourth quarter of fiscal 2026 and a narrower adjusted EBITDA loss than in the comparable period. On its earnings call, management also highlighted newly granted Malaysian licenses for vapor products and nicotine pouches, which it said position the company for fiscal 2027.

How did ISPR shares react?

The shares last traded at 1.30, a decline of 9.72% from the prior close of 1.44, with an intraday range of 1.21 to 1.49, as of 20:00 GMT on 16 September 2026. The fall was company-specific: the S&P 500 tracker closed down 0.44% and the Nasdaq 100 tracker was roughly flat that session.

What is adjusted EBITDA and why does a narrower loss matter?

Adjusted EBITDA is earnings before interest, taxes, depreciation and amortisation, with certain one-off or non-cash items excluded. It is used as a rough proxy for operating cash generation. A narrowing loss means the gap to breakeven is closing, but it is still a loss, so the company continues to consume cash.

Why are the Malaysian licenses significant?

Licenses give Ispire a legal, regulated route to sell both vapor products and nicotine pouches in Malaysia. Where a government formalises a previously unregulated category, licensed sellers gain distribution access and pricing power that unlicensed competitors lose. The licenses are permission to compete, however, not guaranteed revenue.

What US regulatory pressures is the company diversifying away from?

Vapor manufacturers selling into the United States face a product authorisation regime that has cleared relatively few products, state-level flavour restrictions, and enforcement against unauthorised imports. That makes demand unpredictable while compliance costs stay fixed, which is a heavy burden for a small manufacturer.

What should investors watch in fiscal 2027?

Three things: whether the adjusted EBITDA loss narrows for several consecutive quarters rather than one; whether revenue growth holds its rate as the comparison base grows; and how the Malaysian build-out is funded, since raising equity at a share price of 1.30 would dilute existing holders.

Sources

• Ispire Technology Inc (ISPR) (Q4 2026) Earnings Call Highlights: Malaysia Licenses Set Stage ... — GuruFocus

Photo: Journal of Studies on Alcohol and Drugs · Pexels Licence — source